Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

Rhea-AI Summary

DBVT (NYSE Euronext Paris, ISIN: FR0010417345) announced the total number of shares and voting rights as of December 31, 2025 in accordance with Article 223-16 of the AMF General Regulations.

The company reported a total number of shares of 232,207,589, a total gross of voting rights of 232,207,589, and a total net of voting rights of 232,133,009 (net excludes shares without voting rights). A PDF attachment is available for the detailed statement.

Key Figures

Total shares 232,207,589 Outstanding as of 12/31/2025

Total gross voting rights 232,207,589 As of 12/31/2025 under AMF Article 223-16

Total net voting rights 232,133,009 Excludes shares without voting rights, as of 12/31/2025

Market Reality Check

$17.01 Last Close

Volume Volume 376,498 vs 20-day average 716,660 (relative volume 0.53x) ahead of this neutral share-count notice. low

Technical Price $19.05 is trading above the 200-day MA at $11.17 before this filing.

Peers on Argus

DBVT was down 0.63% while peers CADL, OMER, ANNX, CAPR, and NGNE showed declines ranging from -2.42% to -8.04%. Despite broad peer weakness, momentum scanners did not flag a coordinated sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 16	Phase 3 results	Positive	-1.7%	Positive Phase 3 VITESSE topline data for VIASKIN Peanut in children 4–7.
Dec 02	Capital structure update	Neutral	-0.6%	Monthly disclosure of total shares and voting rights as of Nov 30, 2025.
Nov 11	Trial progress	Positive	-1.8%	Completion of last patient visit in VITESSE Phase 3 VIASKIN Peanut trial.
Nov 04	Conference participation	Neutral	+0.8%	Announcement of participation in Guggenheim Healthcare Innovation Conference.
Nov 03	Executive appointment	Positive	-2.7%	Appointment of a new Chief Commercial Officer for VIASKIN Peanut strategy.

Pattern Detected

Recent history shows several positive clinical and strategic updates followed by negative next-day moves, suggesting a pattern where upbeat headlines did not translate into immediate price strength.

Recent Company History

Over the last few months, DBV reported key milestones, including completion of last patient visits in the VITESSE Phase 3 trial and later announcing positive topline results for the VIASKIN Peanut patch (Dec 16, 2025). Strategic developments included appointing a Chief Commercial Officer and conference participation. The company also began issuing regular monthly updates on total shares and voting rights, such as the Nov 30, 2025 disclosure. This new Dec 31, 2025 voting-rights notice continues that reporting cadence without adding new clinical or financial catalysts.

Market Pulse Summary

The stock dropped -10.8% in the session following this news. A negative reaction despite this routine update would fit a pattern where various announcements, including positive VITESSE Phase 3 data on Dec 16, 2025, were followed by next-day declines. Since this filing mainly details total shares and voting rights as of Dec 31, 2025, it adds little new information versus the Nov 30, 2025 update. Any sharp downside could therefore reflect broader risk sentiment rather than a fundamental change in this disclosure.

Key Terms

isin financial

"Market : NYSE Euronext Paris ISIN Code: FR 0010417345"

A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.

AI-generated analysis. Not financial advice.

Information Regarding the Total Number of Voting Rights and 
Total Number of Shares of the Company as of December 31, 2025

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris
ISIN Code: FR 0010417345

Date	Total number of shares	Total number of voting rights
12/31/2025	232,207,589	Total gross of voting rights: 232,207,589
		Total net* of voting rights: 232,133,009

* Net total = total number of voting rights attached to shares – shares without voting rights

Attachment

• PDF Version

FAQ

What are the total number of shares and voting rights for DBVT as of December 31, 2025?

DBVT reported 232,207,589 total shares, 232,207,589 gross voting rights, and 232,133,009 net voting rights as of Dec 31, 2025.

What is the difference between gross and net voting rights for DBVT (DBVT) on Dec 31, 2025?

Gross voting rights equal all voting rights attached to shares; net voting rights (232,133,009) exclude shares without voting rights.

Where can investors find DBVT's full statement of voting rights for December 31, 2025?

The company published the statement with an attachment PDF alongside the disclosure filed under Article 223-16 of the AMF General Regulations.

Which ISIN and market are listed for DBVT in the December 31, 2025 voting rights disclosure?

The disclosure lists ISIN FR0010417345 and market NYSE Euronext Paris.

Does DBVT's reported share count on Dec 31, 2025 affect shareholder voting power immediately?

The figures define the universe of voting rights at Dec 31, 2025; any change in voting power depends on subsequent transactions or corporate actions after that date.